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Abstract
Background:  The fixed dose combination atovaquone-proguanil is a recently introduced
antimalarial for treatment and prophylaxis of Plasmodium falciparum malaria. It is highly effective
with a good tolerability profile and a convenient prophylactic regimen. Nevertheless, cases of
treatment failure have already been reported, which have been associated to mutations in the
cytochrome b gene of the Plasmodium (pfcytb). The presence of atovaquone-proguanil in vivo
resistance conferring mutations in pfcytb gene in Luanda, Angola, was investigated, in order to make
recommendations on prescribing this antimalarial as prophylaxis for travellers.
Methods:  Two hundred and forty nine blood samples from children hospitalized at Luanda
Pediatric Hospital for malaria were studied. The PCR-RFLP methodology was used in order to
identify pfcytb wild type codon 268 and two point mutations: T802A and A803C.
Results: All samples were identified as wild type for pfcytb gene at codon 268. In the studied
population, no mutations associated to atovaquone-proguanil treatment failure were found.
Prevalence of the studied mutations in the region was estimated to be less than 0.77% (99%
significance level).
Conclusion: Atovaquone-proguanil can be recommended for use by travellers to Luanda with
expected high efficacy. This represents an improvement compared to other currently used
prophylatic antimalarials in this region. However, it is imperative to continue surveillance.
Background
In the past decades, international travel has increased and
more than 125 million international travellers visit
malaria endemic countries every year [1]. This has turned
the attention of scientific and public health authorities to
the problem of imported and introduced malaria. The
leading cause of imported malaria is Plasmodium falci-
parum [2-6] and antibody reaction to the parasite circum-
sporozoite antigen among international travellers has
shown a high prevalence of inoculation [7]. Infection is
especially relevant in sub-Saharan Africa travellers [7].
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Accordingly, the number of imported malaria cases has
increased. There are approximately 30,000 cases of
imported malaria notified per year in non-endemic coun-
tries with important morbidity and mortality [2-6,8].
Both these indices can be lowered by adequate prophy-
laxis. Indeed, most cases of malaria are due to non-com-
pliance or inadequate prophylaxis [4,5,9]. It is, therefore,
imperative to find a chemoprophylactic antimalarial with
a good tolerability and safety profile as well as an attrac-
tive prophylactic regimen.
The fixed-dose combination of 250 mg atovaquone and
100 mg proguanil per tablet (Malarone®) has recently
been introduced for treatment and prophylaxis of P. falci-
parum  malaria. Based on its similarity to ubiquinol,
atovaquone acts on P. falciparum cytochrome b (pfcytb),
affecting the parasite mitochondrial respiratory chain and
collapsing the mitochondria membrane potential [10-
12]. This leads to apoptosis [12]. In addition, the combi-
nation also blocks dihydroorotate dehydrogenase, inhib-
iting pyrimidine synthesis [11,13]. Proguanil enhances
the ability of atovaquone to collapse the mitochondrial
membrane by a mechanism still unexplained [14]. The
combination effectively inhibits the development of the
liver and blood stages of P. falciparum [15-17].
As recently reviewed atovaquone-proguanil is highly
effective as prophylaxis for up to six months [18,19] with
an improved tolerability profile, a more convenient pro-
phylactic regimen and better compliance.
It is now recommended as a prophylactic alternative to
mefloquine or doxycycline in chloroquine-resistant areas
[20]. Nevertheless, in many countries it is considered the
first line antimalarial for prophylaxis in areas of chloro-
quine resistance and for imported malaria treatment
(including emergency treatment) [21,22].
There have been some reports of atovaquone-proguanil
treatment failure in travellers, associated to pfcytb  gene
mutations, particularly at codon 268, namely T802A and
A803C [23-27]. Epidemiologic surveillance of emerging
resistance to this combination can be done by screening
for these mutations.
The presence of atovaquone-proguanil in vivo resistance
conferring mutations in pfcytb gene in Luanda, Angola,
was investigated. This was done in order to estimate the
prevalence of these mutations in this region and make rec-
ommendations on prescribing this antimalarial as proph-
ylaxis for travellers.
Methods
Infected blood samples were obtained from children
younger than 12 years of age hospitalized at Luanda Pedi-
atric Hospital, Angola, during the years of 2003/2004.
Both the hospital and IHMT Ethics Committee approved
all the applied protocols.
An estimated prevalence of mutation T802A and A803C
of 0.77 and 0.96%, respectively, was considered for popu-
lation size calculation [27]. For an expected prevalence of
0.77%, with a significance level of 99%, the size of the
studied population should be at least 213 children (Stat-
Cal, EpiInfoVersion 6, CDC, Atlanta). Samples were indi-
vidually spotted on Whatman no 4 filter paper, after
microscopic confirmation of P. falciparum infection.
Chelex DNA extraction was done according to established
protocols [28]. A modified semi-nested PCR-RFLP
method was carried out to search for polymorphisms in
pfcytb (T802A and A803C) [24,29]. Primer sequences are
presented in Table 1. All amplifications were performed in
an I-Cycler-IQ, BIO-RAD, thermocycler. The first amplifi-
cation using the "OD/OR" primers was designed to pro-
duce a 716 bp fragment in the following conditions: 92°C
(three minutes) (1st segment – 1 cycle); 92°C (30 sec-
onds), 57°C (30 seconds), 72°C (one minute) (2nd seg-
ment – 9 cycles); 92°C (30 seconds), 52°C (30 seconds)
72°C (one minute) (3td segment – 34 cycles); 72°C (three
minutes) (4th segment – 1 cycle). This amplicon contained
all the single point polymorphisms. Reagent concentra-
tions were: 1 mM MgCl2 (Fermentas, Lithuania), 10 µM
primers (MWG-Biotech AG, Germany), 1 mM dNTPs (Fer-
mentas, Lithuania), 120 U Taq polymerase (Fermentas,
Table 1: Primer sequences used for the amplification of pfcytb codon 268.
Primer Sequence
OD 5'-CGCAACAGGTGCTTCTCTTGT-3'
OR 5'-ACAGAATAATCTCTAGCACCAAAAATCAT-3'
WtR 5'-GGTTTACTTGGAACAGTTTTTAACAaTG-3'
802D 5'-GTTTATTTGGAATTATACCTTTATCACATCCTGATAATGCTATC-3'
802R 5'-TAAACCAGCTGGTTTACTTGGAACAGTTTTTAACATTGtt-3'
803D 5'-CCTGAATGGTACTTTCTACCAgTT-3'
Small case indicates base changes to provide digest sites for restriction enzymes to distinguish wild type from mutations at codon 268. O: outer 
PCR; D: direct primer; R: reverse primer; Wt: wild type.Malaria Journal 2006, 5:30 http://www.malariajournal.com/content/5/1/30
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Lithuania), 500 ng DNA template from field samples.
Outer PCR product was further diluted (1:50) and 1 µL of
this solution was used for the second amplification.
In the second amplification (nested or semi-nested ampli-
fication), three different pairs of primers were used,
namely OD/WtR; 802D/802R; 803D/OR to distinguish
between the three polymorphisms. The following condi-
tions were used for amplication: 92°C (three minutes)
(1st segment – 1 cycle); 92°C (30 seconds), 65°C (30 sec-
onds), 72°C (one minute) (2nd segment – 9 cycles); 92°C
(30 seconds), 60°C (30 seconds) 72°C (one minute) (3td
segment – 34 cycles); 72°C (three minutes) (4th segment
– 1 cycle). Reagent concentrations were the same as for the
first amplification. The products of the second amplifica-
tion were confirmed by electrophoresis in ethidium bro-
mide-stained 3% agarose gel.
For RFLP analysis, 4 µL of each nested product was used,
with 0.1 U of each enzyme and specific buffer in a 20 µL
final volume, incubated overnight at 37°C. Table 2 sum-
marizes primer pairs and restriction enzymes used for the
identification of each polymorphism.
The laboratory-established clone K1 of P. falciparum
(pfcytb  wild type) was used as amplification reaction
intrinsic control. Pfmdr1 gene from the 3D7 clone and
serca gene from Plasmodium chabaudi have a cutting site for
Dra-I and Cai-I, respectively. They were used as restriction
reaction positive controls.
Results
Two hundred and forty nine blood samples were col-
lected. DNA was successfully amplified from 224. Figure 1
illustrates the result of restriction of each of the second
amplification products with the corresponding enzyme.
Products of the amplification with primers for the identi-
fication of wild type pfcytb were restricted with Mph1103-
I. Clone K1 and all field samples were cut. None of the
field samples amplified with primers for identification of
T802A (AAT) and A803C (TCT) mutations was cut with
either Dra-I or Cai-I, respectively. According to the enzyme
restriction pattern, all samples were identified as pfcytb
codon 268 wild type.
Discussion
In the studied population, no mutations associated to
atovaquone-proguanil treatment failure were found. Prev-
alence of these mutations in Luanda was estimated to be
less than 0.77% with a 99% significance level. Therefore,
Malarone® can be recommended for use by travellers to
this region with expected high efficacy. This represents an
improvement in view of the known prevalence of resist-
ance against other currently used prophylactic antimalar-
ials.
This was the first work focusing on atovaquone-proguanil
treatment failure associated mutations ever done in this
area. It gives baseline information of the prevalence of
these mutations in the region. After a more extensive
atovaquone-proguanil introduction in the market, future
studies will be important to monitor these numbers.
Screening for the same mutations in Guinea Bissau, Zan-
zibar and Ghana [29,30] were also negative. Limited use
of this antimalarial in endemic countries can explain the
low prevalence of resistance-associated mutations.
Restricted use by travellers will probably not increase pres-
sure selection of mutants.
However, other cases of treatment failure, not associated
to point mutations, have been described [27]. Study of
prevalence of mutations in field samples, especially in
treatment failure cases and travellers using the drug for
prophylaxis, will help understanding the importance of
these mutations in resistance. It is, therefore, imperative
to continue surveillance.
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